Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Chosa

    MCap

    SEK57m

    Last close

    SEK0.80

    ▲ 0.20 (33.33%)

    Vection Technologies

    MCap

    AUD47m

    Last close

    AUD0.04

    ▲ 0.00 (12.90%)

    Metro Bank

    MCap

    GBP684m

    Last close

    GBP1.02

    ▲ 7.90 (8.43%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Actinogen Medical (ASX: ACW)

Last close As at 21/11/2024

AUD0.02

— 0.00 (−4.00%)

Market capitalisation

AUD74m

Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem, a specific and selective 11beta-HSD1 inhibitor designed to treat cognitive impairment (CI), which occurs in chronic neurodegenerative and neuropsychiatric diseases.

The unmet need in chronic neurocognitive disorders is tremendous due to the limited effectiveness of available treatment options. The Phase IIb/III XanaMIA trial will be key for validating the encouraging Xanamem AD data shown to date.

Latest Insights

View More

Healthcare | Update

Actinogen Medical — A$11.1m capital raise completed

Healthcare | Update

Actinogen Medical — Funding in place to complete XanaMIA Phase IIb

Healthcare | Flash note

Actinogen Medical — Further positive XanaCIDD results on depression

Healthcare | Update

Actinogen Medical — XanaCIDD data narrow the focus in depression
Actinogen Medical
Visit Website

Sector

Healthcare

Equity Analyst

Pooya Hemami

Analyst - Healthcare

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Arron Aatkar

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Dr Steven Gourlay

    CEO and MD

  • Michael Roberts

    Head of investor relations

Balance Sheet

Forecast net cash (A$m)

11.3

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (7.4) (3.8) 1.4
Relative (8.2) (8.7) (14.7)
52 week high/low A$0.1/A$0.0

Financials

Actinogen’s Xanamem is a once-daily oral selective 11beta-HSD1 inhibitor, designed to cross the blood-brain barrier and target excess brain cortisol, which has been associated with cognitive impairment in chronic brain conditions such as Alzheimer’s disease (AD). Positive results in healthy adults demonstrated the drug’s initial efficacy, while an analysis of biomarker-positive (pTau-181) patients using plasma samples from the previous XanADu study in mild AD also showed clinical activity using the validated CDR-SB scale. Actinogen’s Phase IIb/III XanaMIA trial in patients with biomarker-confirmed early AD is underway, and it plans to report interim data in mid CY25. Given the completion of the A$11.1m capital raising announced in September, Actinogen expects to be fully funded through this trial’s completion in mid CY26. It is also evaluating Xanamem as a treatment for depression symptoms in major depressive disorder, following positive efficacy signals shown in the Phase IIa XanaCIDD study.

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (fd) (c) P/E (x) P/CF (x)
2023A 4.9 (10.6) (8.9) (0.495) N/A N/A
2024A 9.9 (12.8) (11.4) (0.525) N/A N/A
2025E 7.3 (12.0) (11.4) (0.394) N/A N/A
2026E 14.1 (19.4) (19.3) (0.625) N/A N/A

Research

Update

Healthcare

Actinogen Medical — Funding in place to complete XanaMIA Phase IIb

Flash note

Healthcare

Actinogen Medical — Further positive XanaCIDD results on depression

Healthcare

Update

Actinogen Medical — A$11.1m capital raise completed
View All

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free